X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with PLETHICO PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs PLETHICO PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. PLETHICO PHARMA FRESENIUS KABI ONCO./
PLETHICO PHARMA
 
P/E (TTM) x 22.1 -1.1 - View Chart
P/BV x 3.1 0.0 18,573.0% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   PLETHICO PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
PLETHICO PHARMA
Mar-14
FRESENIUS KABI ONCO./
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs176395 44.6%   
Low Rs7931 250.8%   
Sales per share (Unadj.) Rs37.7604.4 6.2%  
Earnings per share (Unadj.) Rs5.132.5 15.7%  
Cash flow per share (Unadj.) Rs6.751.3 13.1%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.5473.6 9.0%  
Shares outstanding (eoy) m158.2334.08 464.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.4 957.7%   
Avg P/E ratio x25.06.6 380.8%  
P/CF ratio (eoy) x18.94.2 455.9%  
Price / Book Value ratio x3.00.5 664.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1357,262 277.2%   
No. of employees `0001.2NA-   
Total wages/salary Rs m7031,596 44.1%   
Avg. sales/employee Rs Th5,176.2NM-  
Avg. wages/employee Rs Th610.4NM-  
Avg. net profit/employee Rs Th699.6NM-  
INCOME DATA
Net Sales Rs m5,96320,598 28.9%  
Other income Rs m18386 4.7%   
Total revenues Rs m5,98120,984 28.5%   
Gross profit Rs m1,4302,818 50.8%  
Depreciation Rs m258642 40.2%   
Interest Rs m-261,593 -1.6%   
Profit before tax Rs m1,216969 125.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342-138 -247.3%   
Profit after tax Rs m8061,107 72.8%  
Gross profit margin %24.013.7 175.3%  
Effective tax rate %28.1-14.3 -196.9%   
Net profit margin %13.55.4 251.5%  
BALANCE SHEET DATA
Current assets Rs m5,10218,877 27.0%   
Current liabilities Rs m2,38511,896 20.1%   
Net working cap to sales %45.633.9 134.4%  
Current ratio x2.11.6 134.8%  
Inventory Days Days15036 417.5%  
Debtors Days Days113198 57.3%  
Net fixed assets Rs m5,1489,861 52.2%   
Share capital Rs m158341 46.4%   
"Free" reserves Rs m6,55612,331 53.2%   
Net worth Rs m6,73216,139 41.7%   
Long term debt Rs m9524,706 20.2%   
Total assets Rs m10,38833,146 31.3%  
Interest coverage x-45.81.6 -2,847.0%   
Debt to equity ratio x0.10.3 48.5%  
Sales to assets ratio x0.60.6 92.4%   
Return on assets %7.58.1 92.2%  
Return on equity %12.06.9 174.5%  
Return on capital %14.612.3 118.8%  
Exports to sales %74.521.4 348.4%   
Imports to sales %24.815.2 162.7%   
Exports (fob) Rs m4,4414,402 100.9%   
Imports (cif) Rs m1,4773,136 47.1%   
Fx inflow Rs m5,2984,402 120.3%   
Fx outflow Rs m1,7723,184 55.7%   
Net fx Rs m3,5251,219 289.3%   
CASH FLOW
From Operations Rs m1,2742,437 52.3%  
From Investments Rs m-1,204-6,265 19.2%  
From Financial Activity Rs m-1962,490 -7.9%  
Net Cashflow Rs m-126-1,337 9.4%  

Share Holding

Indian Promoters % 0.0 82.7 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 4.3 7.0%  
FIIs % 9.6 5.5 174.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 7.5 121.3%  
Shareholders   42,599 10,665 399.4%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   STRIDES SHASUN LTD  AJANTA PHARMA  UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS